ABSTRACT: Protein degradation is the cell's mechanism of eliminating misfolded or unwanted proteins. The pathway by which proteins are degraded occurs through the ubiquitin-proteasome system. Ubiquitin is a small 9-kD (kDa) protein that is attached to proteins. A minimum of four ubiquitins are required for proteins to be recognized by the degradation machinery, known as the 26S proteasome. Defects in ubiquitination have been identified in a number of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. We sought to exploit the delicate balance between protein synthesis and degradation to treat cancer by designing a chimeric molecule, known as Protac (Proteolysis Targeting Chimeric molecule). Protacs are heterobifunctional nanomolecules that are approximately 10 nm in size and can recruit proteins that cause cancer to the ubiquitin-proteasome machinery for degradation. In this review, we discuss the development of this novel technology for the treatment of cancer. (Pediatr Res 67: 505-508, 2010)
UBIQUITIN-PROTEASOME SYSTEM
The ubiquitin-proteasome system (UPS) is a major pathway that regulates the levels of intracellular proteins and provides a fine balance between protein synthesis and degradation. In addition to protein synthesis, the UPS regulates a number of critical functions within cells, including cell cycle progression, apoptosis, protein localization, growth signaling pathways, autophagy, and DNA repair (1) (2) (3) . Multiubiquitination of proteins with a minimum of four ubiquitins attached to proteins results in degradation by the 26S proteasome (4) . Monoubiquitination regulates other cellular functions, e.g. transcription, localization, signal transduction, DNA repair (1, 5) . Recently, a class of proteases known as deubiquitinating enzymes (DUBs) have been identified, which act to remove or remodel ubiquitin moieties from target proteins (6) . Because the UPS plays an important role in so many functions, they are likely targets for cancer therapy.
Ubiquitin is a small 9-kDa protein that consists of 76 amino acids and is conserved throughout evolution from yeast to humans (7) . The UPS consists of ubiquitin, a three-enzyme complex known as the ubiquitin ligase, and the 26S proteasome (8) . The components of the UPS exist in the cytoplasm and the nucleus (5,9,10) and act in a sequential manner to ubiquitinate target proteins. First, the ubiquitin activating enzyme or E1 attaches the ubiquitin to a substrate in an ATP-dependent reaction. Second, the ubiquitin is transferred to the ubiquitinconjugating enzyme or E2, which transfers the ubiquitin together with an E3 ubiquitin ligase, to the protein (Fig. 1) . The E3 ubiquitin ligase confers specificity to the protein target. In the human genome, there is one E1 enzyme, approximately 50 E2 enzymes, and more than 600 E3 enzymes (4, 5, 11, 12) .
Mutations or abnormal regulation of ubiquitin ligases have been identified in cancer. In addition, several targets of E3 ubiquitin ligases are mutated or are overexpressed in tumors. Among these proteins are the tumor suppressors p53, (breast cancer1, early onset) BRCA1, cyclin inhibitor kinase inhibitor 1B (p27Kip1), and oncogenes epidermal growth factor receptor, cyclin E, Von Hippel-Lindau, human papilloma virus protein E6-associated protein (AP), and most recently the E3 ligase casitas B-lineage lymphoma (c-Cbl) in myeloid leukemia (5, 13) . Therefore, E3 ligases are potential targets for cancer therapy.
PROTACS TO TARGET CANCER-CAUSING PROTEINS FOR DESTRUCTION
We developed an approach to treat human disease that recruits a cancer-causing protein to an E3 ligase for subsequent ubiquitination and degradation. This technology is known as Protac or proteolysis targeting chimeric molecule. The concept was first described by Zhou et al. (14) in which they used a gene therapy approach to target proteins for ubiquitination and degradation. Zhou et al. made a fusion protein between a subunit of the ubiquitin ligase known as Skp1-Cullin-F-box protein (SCF) in yeast, cell division cycle protein 4 (Cdc4), with the binding partner of the phosphorylated retinoblastoma (Rb) protein, known as E7N (N-terminus of the human papilloma virus E7 protein). The fusion protein recruited the pRb to the SCF ubiquitin ligase resulting in the ubiquitination and degradation of Rb (14) . Unfortunately, this technology was limited by low efficiency of transduction and use of potentially harmful lentiviruses, thereby making it difficult to translate this to clinical application (14) .
The goal of Protac technology is to create a chimeric molecule that bridges any cancer-causing protein to an E3 ligase. In terms of its structure, Protacs consist of one moiety, e.g. a peptide, which is recognized by the E3 ligase. This moiety is then chemically and covalently linked to a small molecule or a protein that recognizes the target protein. In this manner, the chimeric molecule would bring the target protein to the E3 ligase in close enough proximity for the ligase to attach ubiquitins onto the protein, thereby resulting in degradation (Fig. 2 ). Other advantages of Protacs include the fact that it is catalytic and can be used to recruit any protein that exists in a multisubunit complex (15) .
In addition to the use of Protacs for the treatment of human disease, these molecules provide a chemical genetic approach to "knock down" proteins to study their function (16) . Furthermore, Protacs are specific and do not require transfections or transduction. Protacs can be directly applied to cells or injected into animals without the use of vectors. Given the increased number of E3 ligases in the human genome, the possibilities for different combinations of Protacs that target specific disease-causing proteins to different ligases are unlimited. This review describes general strategies of testing the efficacy of Protacs using two E3 ligases as examples: Skp1-Cullin-Fbox-Hrt1 (SCF
␤-TRCP
) and Von Hippel Lindau (VHL) (17, 18) . Three different targets will be described: methionine aminopeptidase-2 (MetAP-2), estrogen receptor (ER), and androgen receptor (AR).
PROTACS TARGET PROTEINS THAT BIND COVALENTLY FOR UBIQUITINATION AND DEGRADATION
As proof of principle, we first generated a Protac molecule that binds to the protein MetAP-2 for ubiquitination and degradation. MetAP-2 cleaves the N-terminal methionine from nascent polypeptides and is one of the targets of angiogenesis inhibitors fumagillin and ovalicin (19 -21) . Ovalicin binds covalently to MetAP-2 at the His-231 active site. Inhibition of MetAP-2 is thought to block endothelial cell proliferation by causing G1 arrest (22) . MetAP-2 is a stable protein that is not known to be ubiquitinated or an endogenous substrate of the E3 ligase SCF ␤-TRCP . For these reasons, Met-AP2 was chosen to be the initial protein to test Protacs.
The multisubunit ubiquitin ligase, SCF ␤-TRCP , was selected because the F-box protein ␤-TRCP/E3RS was previously shown to bind to IB␣ (inhibitor of NFB␣) through a minimal phosphopeptide sequence, DRHDSGLDSM (23, 24) . This 10 amino acid phosphopeptide was chemically linked to ovalicin to form the Protac as previously described (25) . Our results demonstrated that in vitro not only was Protac able to bind to MetAP-2, but it also induced its ubiquitination. Furthermore, proteasomes in Xenopus extracts could degrade this MetAP-2-Protac complex (25) .
PROTACS TARGET PROTEINS FOR UBIQUITINATION AND DEGRADATION THROUGH NONCOVALENT INTERACTIONS
The next challenge was to demonstrate that Protacs could associate cancer-causing proteins through noncovalent interactions. Steroid hormone receptors and their ligands associate through high affinity interactions. Both the ER and AR are members of the steroid hormone receptor superfamily whose ligands (estradiol and testosterone, respectively) have been well defined and implicated in tumorigenesis. The ER has been implicated in the progression of breast cancer (26 -28) . Similarly, hormone-dependent prostate cancer cells grow in response to androgens (29, 30) . Therefore, both ER and AR are excellent targets for Protac technology. To target ER for ubiquitination and degradation, we synthesized a version of Protac containing the IB␣ phosphopeptide linked to estradiol (the ligand for ER) (31). Not only was Protac able to ubiquitinate purified ER efficiently in vitro, but the ubiquitinated ER was effectively degraded by a purified preparation of the yeast proteasome (31) .
DEVELOPMENT OF PROTACS TO TARGET PROTEINS IN CELLS
Clinical application of Protacs is dependent on successful ubiquitination and degradation of the protein target by endogenous ubiquitin ligases and proteasomes within cells. Because the first generation of Protacs contained a phosphopeptide from IB␣, the molecule was found to be very polar and did not penetrate into cells. Microinjection of this version of Protac was successful (31); however, this approach would not be viable in clinical practice.
To this end, a HIF1␣-DHT Protac was synthesized to increase permeability. Given the lack of small molecules that bind to E3 ligase, the seven amino acid sequence ALAPYIP of HIF1, a natural substrate of VHL, was chosen for the E3 recognition domain of this HIF1-Protac (16) . The HIF1 sequence has been demonstrated to be the minimum recognition domain for the von Hippel-Lindau tumor suppressor protein (VHL) (17, 18) . VHL is part of the VBC-Cul2 E3 ubiquitin ligase complex. Under normoxic conditions, a proline hydroxylase catalyzes the hydroxylation of hypoxia inducible factor 1␣ (HIF1␣) at P564 (32). P564 is the central proline in the ALAPYIP sequence, resulting in recognition and polyubiq- uitination by VHL. HIF1␣ is constitutively ubiquitinated and degraded under normoxic conditions (17, 18) . In addition, a poly-D-arginine tag derived from HIV tat was added to the carboxyl terminus of the peptide sequence to confer cell permeability and prevent nonspecific proteolysis (Fig. 3 ) (33, 34) . This Protac should then enter the cell, be recognized and hydroxylated by a prolyl hydroxylase, and subsequently be bound by both the VHL E3 ligase and the target, AR.
To test this version of HIF1-Protac, we bath applied 293 cells stably expressing the androgen receptor-green fluorescent protein (AR-GFP) fusion protein with Protac, resulting in complete disappearance of AR-GFP signal within hours after treatment (Fig. 4) (31) . This effect was completely inhibited by pretreatment of cells with the proteasome inhibitor epoxomicin (31). Our results suggested that Protacs could in fact degrade specific cancer-promoting targets within cells, provided that the chimeric molecules could permeate into cells.
PROTACS TO TARGET ENDOGENOUS PROTEINS IN CANCER CELLS
Despite the encouraging results of the HIF1-testosterone Protacs in GFP-AR expressing 293 human embryonic kidney cells, this does not represent the endogenous AR expressed in prostate cancer cells. Therefore, we next tested whether Protacs were effective in AR positive prostate cancer cells and ER positive breast cancer cells. When androgen-dependent LnCaP prostate cancer cells were treated with HIF1-testosterone Protac, we observed a significant decrease in the levels of endogenous AR and inhibition of proliferation (35) . In androgenindependent cells, there was no effect of Protac on AR levels or cell proliferation. Similarly, when estrogen-dependent MCF7 cells were treated with HIF1-estrogen Protac, cells stopped growing and ER levels decreased (35) . These results demonstrated that when hormone-dependent cells are treated with Protac, not only are the receptors down-regulated, but they are also functionally inhibited. Interestingly, the immediate effects of Protacs on prostate and breast cancer cells appear to be growth arrest in G1. With prolonged exposure, the cells entered apoptosis, similar to what is observed under conditions of androgen or estrogen-deprivation. This further supports the efficacy of Protacs through its ability to "starve" cells of their hormone dependency, resulting in cell death.
Despite these encouraging results, the IC50 for Protacs remained high for a possible drug for clinical application. The lowest IC50 with derivatization was 3.8 M for prostate and breast cancer cells, which is still quite high. Other groups have since confirmed the effectiveness of Protacs in prostate cancer cells using a testosterone-based Protac (36) . Clearly, further development of Protacs is clearly needed to bring this technology to clinical trials in humans.
Other applications of Protacs have been recently reported (20, 37) . Protacs were used to block the aryl hydrocarbon receptor (AHR) pathway. Activation of AHR by agonists and environmental pollutants, such as dioxin, leads to carcinogenesis. To down-regulate this pathway, Protacs were design with the ligand for AHR covalently linked to HIF1 peptide to target AHR to the VHL E3 ubiquitin ligase. This chimeric molecule was shown to induce degradation of AHR in epithelial cells and inhibit its function at a concentration of 10 M (20,37). Therefore, as seen with our own data, although Protacs are effective, the concentrations necessary for their effects are quite high.
To overcome the problem with permeability and penetration into tumor cells, one approach is to replace the peptide with a small molecule that binds either the protein target or the E3 ligase. This may result in more efficient Protacs and provide enough reagent to test these molecules in vivo using mouse models of prostate and breast cancer. Another hurdle is the expense and labor of producing peptides as drugs for cancer therapy. The chemistry involved is time consuming and expensive, therefore not practical. To this end, Schneekloth et al. (38) designed a Protac that consisted of a nonsteroidal AR ligand and the mouse double minute (MDM2) ligand known as nutlin (39) . In this version of Protac, a polyethylene glycol (PEG)-based linker was used to promote stability. The selective androgen receptor modulator (SARM)-nutlin Protac was able to recruit the AR to the E3 ubiquitin ligase MDM2, resulting in ubiquitination and degradation of the AR at a concentration of 10 M. The model system used was a HeLa cell line expressing the AR. The degradation was inhibited by the proteasome inhibitor epoxomicin, suggesting that the Protac induced AR degradation through the UPS (38) . The benefit of Protac technology is that it is versatile and can theoretically recruit any cancer or diseasepromoting protein to an E3 ubiquitin ligase for degradation (Fig. 5) . Despite the advances in Protac technology, the molecule will require further derivation and chemical modifications before use in animal models and humans.
CONCLUSIONS AND SUMMARY
Protacs provide an entirely new nanotechnology-based approach to target cancer-causing proteins for ubiquitination and degradation. Experiments over the past decade have demonstrated that Protacs are specific, versatile, and biologically active to induce degradation of proteins that promote tumorigenesis and inhibit the growth of cancer cells. Future directions will focus on further development of Protacs to convert them into more practical drugs for clinical application.
